Rigel (NASDAQ: RIGL) EVP awarded 19,430 RSU-linked common shares

Rhea-AI Filing Summary

Santos David A reported acquisition or exercise transactions in this Form 4 filing.

Rigel Pharmaceuticals executive David A. Santos reported an equity grant. He was awarded 19,430 shares of common stock at a price of $0.00 per share, tied to a Restricted Stock Unit award. The RSUs will vest quarterly over three years, starting on March 31, 2026, increasing his direct ownership to 62,870 shares as they vest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos David A

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		19,430(1)	A	$0	62,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

	/s/ Raymond Furey (Attorney-in-Fact)	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RIGL executive David A. Santos report on this Form 4?

David A. Santos reported an equity grant of 19,430 shares of Rigel Pharmaceuticals common stock. These shares relate to a Restricted Stock Unit award that vests over three years, rather than an immediate open-market purchase or sale.

How many Rigel (RIGL) shares were granted to David A. Santos?

The filing shows a grant of 19,430 shares of Rigel Pharmaceuticals common stock. These shares are tied to Restricted Stock Units that will be acquired upon vesting, rather than being fully owned at the grant date.

What is the vesting schedule for David A. Santos’s RIGL Restricted Stock Units?

The Restricted Stock Units vest quarterly over three years. The first quarterly vesting occurs on March 31, 2026, with additional quarterly vestings thereafter until the full 19,430-share award has vested, assuming continued service and satisfaction of applicable conditions.

Did David A. Santos buy or sell Rigel (RIGL) shares in the market?

No open-market buy or sell is reported. The Form 4 reflects a grant or award acquisition of 19,430 shares via Restricted Stock Units, with a transaction price of $0.00 per share, rather than a cash purchase or sale.

How many Rigel (RIGL) shares does David A. Santos own after this Form 4 transaction?

After the reported grant, total direct common stock holdings are listed as 62,870 shares. The newly awarded 19,430 shares will be acquired over time as the related Restricted Stock Units vest quarterly across the three-year vesting period.